<DOC>
	<DOCNO>NCT01146652</DOCNO>
	<brief_summary>Primary Objective : Assess long term safety sarilumab patient rheumatoid arthritis . Secondary Objective : Assess long term efficacy sarilumab patient rheumatoid arthritis .</brief_summary>
	<brief_title>Long Term Evaluation Sarilumab Rheumatoid Arthritis Patients ( SARIL-RA-EXTEND )</brief_title>
	<detailed_description>The maximum duration study may 523 week : - Up 1-week screening , - At least 264 week open label treatment phase 516 week maximum - 6-week post-treatment follow-up require per protocol .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Inclusion criterion : Patients Rheumatoid Arthritis ( RA ) previously randomize sarilumab RA clinical program : e.g. , EFC11072 study , ACT11575 study , EFC10832 study , SFY13370 , EFC13752 study . Exclusion criterion : Patients adverse event lead permanent study drug discontinuation prior study . Patients abnormality ( y ) adverse event ( ) per investigator judgment would adversely affect participation patient study . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>